Financial Survey: BioLargo (BLGO) & Its Competitors

BioLargo (NASDAQ:BLGOGet Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares BioLargo and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioLargo $12.23 million -$3.50 million -8.25
BioLargo Competitors $6.64 billion $206.77 million 62.91

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioLargo has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.78, meaning that their average stock price is 78% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
BioLargo Competitors -568.74% 5.73% -0.15%

Analyst Ratings

This is a summary of recent recommendations for BioLargo and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
BioLargo Competitors 139 1268 1591 46 2.51

As a group, “Chemicals & allied products” companies have a potential upside of 10.18%. Given BioLargo’s peers higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.

Summary

BioLargo peers beat BioLargo on 8 of the 10 factors compared.

About BioLargo

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.